• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ADMA Biologics Inc (Amendment)

    2/14/24 4:49:51 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email
    SC 13G/A 1 d763698dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)*

     

     

    ADMA Biologics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    000899 10 4

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 000899 10 4

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,433,369

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,433,369

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,433,369

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     2.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 000899 10 4

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,433,369

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,433,369

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,433,369

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     2.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 000899 10 4

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,433,369

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,433,369

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,433,369

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     2.8%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    ADMA Biologics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    465 State Route 17

    Ramsey, New Jersey 07446

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    000899 10 4

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 225,967,668 outstanding shares of Common Stock as disclosed by the Issuer in its Form 10-Q filed on November 8, 2023.


    The Master Fund directly holds 6,433,369 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    /s/ Joseph Edelman

    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    Get the next $ADMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    7/6/2021$10.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

      Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume The 20% Yield Enhancement Will Benefit Both ASCENIV and BIVIGAM RAMSEY, N.J. and BOCA RATON, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing,

      4/28/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by ADMA Biologics Inc

      SCHEDULE 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      5/9/25 4:14:39 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by ADMA Biologics Inc

      10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 5:15:53 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

      5/7/25 4:12:24 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on ADMA Biologics with a new price target

      Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

      7/19/23 9:02:26 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on ADMA Biologics with a new price target

      Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00

      10/13/22 7:18:25 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics upgraded by Raymond James with a new price target

      Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00

      11/11/21 6:21:44 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    See more
    • ADMA Biologics Set to Join S&P SmallCap 600 Index

      RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

      9/17/24 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.

      RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA's Board. "Young is a recognized leader in the healthcare sector and his deep strategic and financial experience

      10/18/21 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $450,660 worth of shares (21,000 units at $21.46), decreasing direct ownership by 0.29% to 2,055,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/16/25 9:00:26 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 18,920 shares, decreasing direct ownership by 4% to 490,425 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      4/2/25 9:00:38 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Grossman Adam S exercised 15,000 shares at a strike of $5.40 and sold $397,320 worth of shares (21,000 units at $18.92), decreasing direct ownership by 0.29% to 2,061,850 units (SEC Form 4)

      4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

      3/21/25 9:00:15 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

      SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/12/24 1:34:17 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/8/24 9:21:37 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ADMA Biologics Inc

      SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

      11/4/24 11:00:41 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADMA
    Financials

    Live finance-specific insights

    See more
    • ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

      1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income(3) of $33.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately $171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue Growth and Margin Expansion Opportunity FY 2025 and 2026 Total Revenue Guidance Increased to More than $500 Million and $625 Million, Respectively FY 2025 Adjusted Net In

      5/7/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

      RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uni

      4/30/25 7:00:00 AM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024 High-Titer Plasma Supply Contracts Expected to Provide Foundation for Durable ASCENIV Revenue Growth Through Late 2030s FDA Approval of Yield Enhancement Production Process Anticipated by Mid-2025

      3/3/25 4:05:00 PM ET
      $ADMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care